INKT logo

INKT
MiNK Therapeutics Inc

1,781
Mkt Cap
$54.82M
Volume
21,535.00
52W High
$76.00
52W Low
$6.34
PE Ratio
-3.72
INKT Fundamentals
Price
$11.04
Prev Close
$11.47
Open
$11.49
50D MA
$10.78
Beta
0.62
Avg. Volume
796,738.76
EPS (Annual)
-$2.93
P/B
-3.65
Rev/Employee
$0.00
$39.43
Loading...
Loading...
News
all
press releases
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a b...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Positive Outlook for INKT Earnings
MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will po...
MarketBeat·9d ago
News Placeholder
MiNK Therapeutics Q4 Earnings Call Highlights
MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform during its fourth quarter and year-end 2025 financial results conference call, highlighting updated clinical observations in solid tumors, plans to initiate randomized testing in s...
MarketBeat·12d ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold...
MarketBeat·1mo ago
News Placeholder
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.read more...
Benzinga·1mo ago
News Placeholder
Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare
Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW
24-7 Market News·1mo ago
News Placeholder
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally
MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.read more...
Benzinga·1mo ago
News Placeholder
Why Did INKT Stock Jump 30% Today?
MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.
Stocktwits·1mo ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...
MarketBeat·3mo ago
<
1
2
...
>

Latest INKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.